Home | Contact Us  
corner
farLeft
     
Tempero’s mission is to develop next-generation therapies that selectively suppress Th17-cells and enhance specialized Treg cells. We believe that therapies that modulate only select arms of the immune response are predicted to effectively treat autoimmune disorders such as multiple sclerosis, inflammatory bowel disease, psoriasis, type 1 diabetes and rheumatoid arthritis without broadly suppressing the immune system.
  SPOTLIGHT  
 

Tempero’s discovery of class IIa HDAC inhibitors is reported in Nature Chemical Biology March 24, 2013.  To read article click here.

Tempero’s Jianfei Yang presented and was a key note speaker at the International Conference on Clinical & Cellular Immunology on October 22-24, 2012 in Chicago. View program here and abstracts here.

 

 
footer
  © 2009 Tempero Pharmaceuticals. All Rights Reserved.